M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Self-Hypnosis for the Enhanced Recovery After Surgery in Patients with Gynecologic Cancer

Not Applicable

Active, not recruiting

Conditions: Metastatic Cervical Cancer
Malignant Female Reproductive System Neoplasm
Recurrent Malignant Female Reproductive System Neoplasm

Interventions: Other: Best Practice
Procedure: Hypnotherapy
Other: Questionnaire Administration
Other: Quality-of-Life Assessment

First Posted Date: 2020-02-12

Last Posted Date: 2024-10-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 152

Registration Number: NCT04266886

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors

Phase 1

Active, not recruiting

Conditions: Metastatic Malignant Solid Neoplasm
Refractory Malignant Solid Neoplasm
Unresectable Malignant Solid Neoplasm

Interventions: Drug: Avelumab
Drug: Berzosertib

First Posted Date: 2020-02-12

Last Posted Date: 2024-08-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 25

Registration Number: NCT04266912

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Serial Magnetic Resonance Imaging for the Prediction of Radiation-Induced Changes in Normal Tissue of Patients with Oral Cavity or Skull Base Tumors

Phase 4

Recruiting

Conditions: Osteoradionecrosis
Malignant Oral Cavity Neoplasm
Malignant Skull Base Neoplasm

Interventions: Other: Contrast Agent
Procedure: Magnetic Resonance Imaging
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2020-02-11

Last Posted Date: 2024-10-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 425

Registration Number: NCT04265430

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Factors Influencing Cascade Testing Among Women With Hereditary Gynecological Cancers and Their Relatives

Completed

Conditions: Fallopian Tube Carcinoma
Endometrial Carcinoma
Ovarian Carcinoma
Breast Carcinoma
Deleterious DICER1 Gene Mutation
Deleterious SMARCA4 Gene Mutation
Deleterious STK11 Gene Mutation
Deleterious CDH1 Gene Mutation
Primary Peritoneal Carcinoma

Interventions: Other: Interview
Other: Questionnaire Administration
Other: Survey Administration

First Posted Date: 2020-02-05

Last Posted Date: 2024-07-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 46

Registration Number: NCT04257045

Locations: 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study

Phase 2

Terminated

Conditions: Metastatic Breast Carcinoma
Prognostic Stage IV Breast Cancer AJCC v8
Anatomic Stage IV Breast Cancer AJCC v8

Interventions: Drug: Abemaciclib
Drug: Anastrozole
Drug: Fulvestrant
Drug: Letrozole
Drug: Palbociclib
Drug: Ribociclib

First Posted Date: 2020-02-05

Last Posted Date: 2024-12-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 4

Registration Number: NCT04256941

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Itacitinib for the Treatment of Bronchiolitis Obliterans Syndrome After Donor Hematopoietic Cell Transplant

Phase 1

Active, not recruiting

Conditions: Bronchiolitis Obliterans

Interventions: Drug: Itacitinib
Drug: Itacitinib Adipate

First Posted Date: 2020-01-27

Last Posted Date: 2024-10-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 8

Registration Number: NCT04239989

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Scrambler Therapy for the Reduction of Chemotherapy-Induced Neuropathic Pain

Not Applicable

Completed

Conditions: Chemotherapy-Induced Peripheral Neuropathy
Malignant Neoplasm

Interventions: Device: FitBit
Other: Gait Assessment Test
Other: MC5-A Scrambler Therapy
Other: Quality-of-Life Assessment
Procedure: Quantitative Sensory Testing
Other: Questionnaire Administration

First Posted Date: 2020-01-27

Last Posted Date: 2022-03-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 16

Registration Number: NCT04239976

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients with Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Phase 2

Recruiting

Conditions: Myelodysplastic Syndrome
Refractory Myelodysplastic Syndrome
Recurrent Chronic Myelomonocytic Leukemia
Recurrent Myelodysplastic Syndrome
Chronic Myelomonocytic Leukemia
Refractory Chronic Myelomonocytic Leukemia

Interventions: Biological: Canakinumab

First Posted Date: 2020-01-23

Last Posted Date: 2024-10-17

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 76

Registration Number: NCT04239157

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Sleep and Physical Activity Intervention for Increasing Physical Activity in Overweight or Obese and Sedentary African Americans

Not Applicable

Recruiting

Conditions: Behavioral Disorder
Endocrine System Disorder

Interventions: Other: Internet-Based Intervention
Other: Focus Group
Behavioral: Health Education
Other: Interview
Other: Questionnaire Administration

First Posted Date: 2020-01-22

Last Posted Date: 2024-10-08

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 28

Registration Number: NCT04236882

Locations: 🇺🇸
The Univeristy of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer

Phase 1

Terminated

Conditions: Renal Pelvis and Ureter Urothelial Carcinoma

Interventions: Drug: Infigratinib
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Procedure: Surgical Procedure

First Posted Date: 2020-01-14

Last Posted Date: 2025-01-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 15

Registration Number: NCT04228042

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy